bers were chosen for their expertise in risk assessment, exposure assessment, toxicology, epidemiology, biostatistics, health economics, and air pollution regulations. The committee was asked to accomplish the following tasks:
Consider issues important in estimating the health-risk-reduction benefits of air pollution regulations, including the scientific data, risk-assessment approaches, populations affected, baselines used, assumptions, analysis of uncertainty, and identification of key indicators of exposure and population health status.
Critically review methods used for recent estimates of regulatory health benefits.
Identify methods used by federal regulatory agencies and others, recommend standard good-practice guidelines and principles for estimating health benefits, and delineate the data-gathering required to better assess health benefits in the future.
Identify approaches to estimating regulatory health benefits when relevant information is limited.
Where applicable, recommend areas for further research and monitoring.
The committee was not asked to evaluate methods used to estimate other types of benefits, such as improvements in visibility, resulting from air pollution control. The committee also was not asked to review the methods used for economic valuation of health benefits or for regulatory cost analyses.
To accomplish its charge, the committee heard, in public session, presentations from representatives of EPA, the U.S. Senate, the Office of Management and Budget (OMB), and other interested parties; reviewed materials submitted by EPA and others; and reviewed current literature relevant to health benefits estimation. The committee selected for detailed review the health benefits analyses contained in the regulatory impact assessments (RIAs) prepared by EPA for the following rule-makings: (1)“Particulate Matter and Ozone National Ambient Air Quality Standards”